Income statement, balance sheet and cash flow statement for the last 7 fiscal years, taken from the XBRL data MOLECULAR PARTNERS AG files with the SEC in its annual reports.
In CHF millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
20.4
9.34
9.75
190
7.04
4.97
0
Research and development
43.5
56.1
55.7
50.7
48.8
48.6
40.2
Selling, general and administrative
13.5
11.6
17.5
22.2
19.4
17.6
15.2
Operating income
-36.7
-58.3
-63.4
117
-61.1
-61.2
-58.1
Interest expense
1.21
4.82
0.56
0.62
5.16
0.04
5.05
Interest income
1.6
0.37
0.19
1.86
4.28
7.21
1.52
Pre-tax income
-36.3
-62.8
-63.8
118
-62
-54
-61.6
Income tax
0.02
-0.01
0
0
0
0
0
Net income
-36.3
-62.8
-63.8
118
-62
-54
-61.7
EPS, basic
-1.69
-2.51
-2.06
3.63
-1.89
-1.59
-1.65
EPS, diluted
-1.69
-2.51
-2.06
3.54
-1.89
-1.59
-1.65
Balance sheet
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
75.7
134
71.8
87.9
67.3
63.9
82.7
Receivables
2.84
25.7
1.02
1.95
2.32
1.83
Total current assets
178
164
255
192
154
96.9
Property, plant and equipment
9.39
8.15
7.24
Intangible assets
0.35
0.33
0.27
0.21
0.05
0
Total assets
188
173
262
198
159
102
Accounts payable
5.83
7.39
2.14
1.33
1.86
1.77
Total current liabilities
57.7
46.9
17.3
14.4
10.8
11
Lease liabilities
6.04
4.85
3.65
2.44
1.23
2.44
Total liabilities
80.3
65.4
27.1
21.9
16.9
21.8
Retained earnings
-195
-251
-128
-192
-246
-312
Total equity
54.1
107
107
235
176
142
80.3
Total liabilities and equity
188
173
262
198
159
102
Cash flow statement
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-36.3
-62.8
-63.8
118
-62
-54
-61.7
Cash from operations
-1.19
-29
-91
119
-59
-59.2
-51.3
Capital expenditures
-1.03
-1.45
-0.93
-1.18
-0.58
-0.71
-0.71
Cash from investing
-19.8
-21.7
-22.2
-101
44.6
40.5
72.5
Stock issued
0
114
51.5
0
0
17.3
0
Share buybacks
0
0
-0.63
0
0
Cash from financing
-0.23
113
50.6
-1.57
-1.17
14.4
-1.15
Exchange rate effect
-1.99
-4.46
0.7
0.26
-5.1
0.89
-1.36
Net change in cash
-23.2
58
-61.9
16.1
-20.6
-3.44
18.8
Free cash flow
-2.22
-30.4
-91.9
117
-59.6
-60
-52
Interest paid
0.09
0.22
0.58
0.65
0.03
0.03
0.02
Income taxes paid
0
0
0
0
0
0
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. No valuation: the share price is quoted in a different currency than the statements.
Profitability
Metric
Value
How it is calculated
Return on assets (ROA)
-47.3%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-100.0%
Revenue vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
-35.6%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-27.0%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-11.4%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
8.79x
Current assets / current liabilities.
Quick ratio
7.66x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
7.50x
(Cash + short-term investments) / current liabilities.
Liabilities / assets
21.3%
Total liabilities / total assets.
Interest coverage
-11.5x
Operating income / interest expense.
Working capital
CHF 85.8M
Current assets - current liabilities.
Goodwill and intangibles / assets
0.0%
(Goodwill + intangible assets) / total assets.
Efficiency
Metric
Value
How it is calculated
Asset turnover
0.00x
Revenue / average total assets.
Receivables turnover
0.00x
Revenue / average receivables.
Per share
Metric
Value
How it is calculated
EPS, diluted
-CHF 1.65
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-CHF 1.65
Net income per basic share, as reported (split-adjusted).
What was MOLECULAR PARTNERS AG's revenue in fiscal 2025?
MOLECULAR PARTNERS AG reported revenue of CHF 0.0 for fiscal 2025, 100% lower than the year before.
Was MOLECULAR PARTNERS AG profitable in fiscal 2025?
No. It reported a net loss of CHF 61.7M.
How much free cash flow did MOLECULAR PARTNERS AG generate in fiscal 2025?
Cash from operations of CHF 51.3M minus capital expenditures of CHF 714.0K left free cash flow of -CHF 52.0M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.